RVMD Stock Recent News

RVMD LATEST HEADLINES

RVMD Stock News Image - Seeking Alpha

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance & Principal Accounting Officer Steve Kelsey - President of R&D Conference Call Participants Alec Stranahan - Bank of America Faisal Khurshid - SVB Securities Eric Joseph - JPMorgan Marc Frahm - Cowen Michael Schmidt - Guggenheim Partners Chris Shibutani - Goldman Sachs Jay Olson - Oppenheimer Operator Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast.

Seeking Alpha 2022 Nov 07
RVMD Stock News Image - Zacks Investment Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research 2022 Nov 07
RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

GlobeNewsWire 2022 Nov 01
RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the 2022 Wells Fargo Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference.

GlobeNewsWire 2022 Aug 31
RVMD Stock News Image - Zacks Investment Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research 2022 Aug 09
RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, August 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress.

GlobeNewsWire 2022 Jul 28
RVMD Stock News Image - Benzinga

Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 11.25% to $21.82 Wednesday morning after the company announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share. Revolution Medicines says theĀ .

Benzinga 2022 Jul 20
7 of 47